MicroPulse TLT - UK Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Prospective Interventional Study will assess the efficacy of MPTLT in the UK.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Micropulse Laser Trabeculoplasty (532nm) Versus Conventional Laser Trabeculoplasty (532nm)

NCT01788319

Open Angle Glaucoma

COMPLETED NA

MicroPulse Transscleral Laser Cyclophotocoagulation With the Zig Zag Mode in Glaucoma.

NCT05521334

Refractory Glaucoma

COMPLETED NA

Use of Micropulse Trans-Scleral Cyclophotocoagulation Laser (MP-TSCPC) for Glaucoma Patients

NCT05654493

Glaucoma

ACTIVE_NOT_RECRUITING NA

Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma

NCT01956942

Open Angle Glaucoma

COMPLETED NA

MicroPulse Transscleral Laser Therapy and Its Short-term Impact on Ocular Surface

NCT06353776

Conjunctiva Cornea

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We are establishing a National Study of MPTLT procedures, co-ordinating with all UK treatment centres to capture prospectively, details of all MPTLT surgical procedure and outcomes. This will create a National UK Registry of MPTLT, allowing us to comply with NICE requirements while adding to the quality of evidence available to support this minimally invasive therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma Glaucoma Eye Glaucoma, Open-Angle Glaucoma Secondary Glaucoma, Angle-Closure Glaucoma, Neovascular Glaucoma Traumatic Glaucoma Uveitic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MPTLT patients

All UK patients undergoing MPTLT

Micropulse Transscleral laser therapy

Intervention Type DEVICE

Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Micropulse Transscleral laser therapy

Transscleral laser cyclophotocoagulation using the IRIDEX Cyclo G6 machine

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cyclophotocoagulation IRIDEX Cyclo G6

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with glaucoma or ocular hypertension deemed clinically suitable for MPTLT treatment by their treating ophthalmologist; this includes but is not limited to (a) need for lower IOP, (b) need for fewer medications based on side effects, poor compliance, adverse effect on lifestyle or (c) evidence of disease progression based on function or structure
* Risk of invasive surgical procedure deemed too high by patient or surgeon
* Aged 18 years or older
* The ability to understand and comply with the trial consent process and procedures
* Willingness to be part of a national registry
* Ability to attend for follow-up
* Ability to give informed consent, or consent given by relative or carer

Exclusion Criteria

* Clinical situations where in the opinion of the investigator, the ocular surface may be compromised by probe contact, including severe ocular surface inflammation
* Inability to give informed consent
* Unwillingness to have clinical data stored in a secure electronic format
* Inability to comply with the study or follow-up procedures

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No